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Abstract 
Introduction 
Pharmacologic pain management in newborns and infants is often based on limited scientific data. 
To close the knowledge gap, drug-related research in this population is increasingly supported by 
the authorities, but remains very challenging. This review summarizes the challenges of analgesic 
studies in newborns and infants on morphine and paracetamol (acetaminophen).  
Areas covered 
Aspects such as the definition and multimodal character of pain are reflected to newborn infants. 
Specific problems addressed include defining pharmacodynamic endpoints, performing clinical 
trials in this population and assessing developmental changes in both pharmacokinetics and 
pharmacodynamics.  
Expert commentary 
Neonatal and infant pain management research faces two major challenges: lack of clear 
biomarkers and very heterogeneous pharmacokinetics and pharmacodynamics of analgesics. There 
is a clear call for integral research addressing the multimodality of pain in this population and 
further developing population pharmacokinetic models towards physiology-based models. 
Keywords 
Pain, pediatrics, neonates, infants, analgesia, pharmacokinetics, pharmacodynamics, opioids, 
paracetamol, acetaminophen 
1. Introduction 
Only few years ago, doses of commonly used drugs like morphine and paracetamol 
(acetaminophen) in newborns and infants were based on extrapolated data from adults or older 
children. Sufficient knowledge about the efficacy, appropriate dosing and safety of these drugs 
derived from properly designed studies has been lacking for years. However, dose validation and 
the beginning of formulation of evidence-based guidelines for these drugs have now been based on 
a number of clinical trials, population PK/PD studies and research on pain assessment and long-
term outcomes.[1-4] To understand the challenges in designing and conducting clinical 
investigations with analgesic medications in newborns and infants it is important to learn from the 
previous successes and failures in this area. This review will describe and discuss the challenges of 
analgesic research in this population on different levels. We first discuss the pain definition and 
next address the issue of adequate pain assessment. With paracetamol and morphine as model 
drugs, we provide an overview of clinical trials so far, discuss the clinical pharmacology of these 
drugs as well as their short- and long-term effects. Special attention will be paid to premature 
neonates, as research in this population is even more challenging.  
2. Pain 
2.1 Definition of pain and its multimodality 
The International Association for the Study of Pain (IASP) has provided the following definition of 
pain: ‘an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’. They further state that ‘pain is always subjective. 
Each individual learns the application of the word through experiences related to injury in early 
life’. However, as this is not applicable to neonates and infants,[5] they revised this statement and 
added: ‘The inability to communicate verbally does not negate the possibility that an individual is 
experiencing pain and is in need of appropriate pain-relieving treatment’.  
This definition aims to cover the multimodality of pain, as pain is more than nociception and/or 
perception of (possible) noxious stimuli alone. Loeser proposed a pain model which includes four 
components: nociception, pain, suffering and pain behavior[6] (see figure 1). Nociception refers to 
the detection of tissue damage by transducers connected to Aδ and C nerve fibers. The IASP defines 
this as ‘the neural process of encoding noxious stimuli’. Pain occurs at the moment of perception, 
once the signal from the peripheral nerve system reaches the central nervous system (CNS). Pain 
can also occur without input from the peripheral nerve system, for example after CNS damage. Pain 
usually leads to suffering as described by Cassel[7]: a ‘consequence of a physical or psychological 
threat to the integrity of the human being’, which has similarity with ‘actual or potential tissue 
damage’. The fourth component is pain behavior, which includes the whole spectrum from small 
moans in acute short-term pain to frequent doctor visits in cases of chronic pain. This behavior can 
be interpreted by others as having pain. Loeser’s model makes clear that pain is a biopsychosocial 
phenomenon, not merely a biological one.  
 
Figure 1. Depiction of pain multimodality according to Loeser. Adapted with permission from: Loeser JD. 
Pain and suffering. Clin J Pain 2000; 16(2 Suppl): p. S2-6.  
 
2.2 Types of pain 
In neonatal and infant critical care, four different types of pain need to be distinguished:  
 
• Procedural pain, acute pain caused by a short-term procedure such as venipuncture, heel 
lancing or chest drain insertion/-removal.  
 
• Postoperative pain, defined as the pain experienced in the first 24 to 48 hours after surgery.  
 
• ‘Prolonged’ pain, a term increasingly used for pain with a duration >72 hours and 
specifically for the neonatal population.[8, 9] 
 
• Chronic pain, defined as pain persisting beyond the expected tissue healing time. However, 
expected healing times are not clearly delineated. Thus, chronic pain was assumed to 
persist for time periods varying from 1-6 months,[10] but in general practice a duration >3 
months is being used.  
 
These types of pain are important when implementing pain assessment tools both in research and 
clinical practice. It is important to know for what type of pain a tool is validated.  
3. Pain assessment and PD markers 
3.1 Behavioral assessment tools 
Taking the definition of pain into account, it follows that pain can be only reliably assessed by self-
report. In preverbal infants this is not possible and then we have to rely on the interpretation of 
pain behavior. 
A great variety of pain assessment tools has been developed over the past decades and to date, 
more than 40 different tools are available just for pain assessment in neonates and infants.[11]  
Table 1 lists the validated observational pain assessment tools for the use in preverbal children, 
including their indication and age category for which it has been validated. These are recommended 
by several international guidelines.[12-14] 
  
 
 
Pain assessment tool Indication Age category Type of tool 
Premature Infant Pain Profile 
(PIPP)[15-17] 
Procedural and postoperative 
pain 
Premature infants >24 weeks 
GA 
Behavioral , contextual, 
physiologic parameters 
Revised premature Infant Pain 
Profile (PIPP-Revised)[18, 19] 
Procedural pain Premature infants >28 weeks 
GA 
Behavioral and physiologic 
parameters 
Neonatal Pain, Agitation and 
Sedation Scale(N-PASS)[20] 
Procedural and prolonged pain 
Sedation level 
Premature infants >23 weeks 
GA 
Behavioral and physiologic 
parameters 
COMFORTneo scale[21] Prolonged pain 
Sedation level 
Premature infants >24 weeks Behavioral parameters 
COMFORT scale[22, 23] Postoperative pain
Sedation level 
Children 0-18 years Behavioral and physiologic 
parameters 
COMFORT behavior scale[24] Postoperative pain 
Sedation level 
Children 0-3 years 
Children 0-18 years 
Behavioral parameters 
Faces, Legs, Arms, Cry, 
Consolability (FLACC) scale[25, 
26] 
Postoperative pain Children 2 months-7 years Behavioral parameters
Multidimensional Assessment of 
Pain Scale (MAPS)[27] 
Postoperative pain Infants 0-31 months Behavioral and physiologic 
parameters 
Table 1. Validated pain assessment tools according to age and their indication. GA: Gestational Age. 
 
3.2 Physiology-based pharmacodynamic markers 
As behavioral assessment tools are subjective to a certain degree, research efforts have been 
directed at identifying objective pharmacodynamic markers for the estimation of pain. Changes in 
vital signs, such as heart rate and blood pressure, do not serve as a link of pain neurobiology to pain 
behavior, as these autonomous responses to pain may be absent after a noxious stimulus.[24] 
Therefore, physiology-based markers such as near-infrared spectroscopy (NIRS), heart rate 
variability (HRV), skin conductance or pupillary reflex dilatation (PRD) have been studied but are 
not yet sufficiently validated. An overview is given in Table 2. 
 
 
 
Potential outcome measures  Advantages Limitations 
NIRS[28, 29] Non-invasive, continuously monitoring Measures only cortical response;  
aEEG[30] Continuous monitoring Not validated for pain in children <2 years 
Skin conductance[31-34] Non-invasive, continuously monitoring Sympathetic activity may be caused by 
anxiety and/or distress as well 
SSEP[35, 36] Non-invasive, continuously monitoring (when 
repetitive stimuli are being given) 
Only reflects sensory response, not 
validated in infants 
Pupillary reflex dilatation[37, 38] Promising bedside application in older children Sympathetic activity may be caused by 
anxiety and/or distress, practical 
difficulties in infants 
HRV (including ANI)[39-51] Non-invasive, continuously monitoring Sympathetic activity may be caused by 
anxiety and/or distress 
fMRI[52, 53] Good overlap between findings in infants and 
adults, insight in pain beyond the sensory cortex 
Not suitable for clinical application
Salivary cortisol levels Non-invasive collection of sample Delay in laboratory results 
Plasma cortisol levels[54-56] Suitable for both short- and long-term pain Delay in laboratory results, sampling 
restricted in neonates 
Plasma adrenalin levels[54, 57]  Delay in laboratory results, sampling 
restricted in neonates, less sensitive than 
noradrenalin 
Plasma noradrenalin levels[54, 57] Significantly reduced by analgesics Delay in laboratory results, sampling 
restricted in neonates 
Table 2. Potential pharmacodynamic markers in neonates and infants.  
aEEG: Amplitude-integrated electroencephalography; ANI: Analgesia Nociception Index; fMRI: 
functional magnetic resonance imaging; HRV: Heart rate Variability; NIRS: Near-infrared 
spectroscopy; SSEP: Somatosensory Evoked Potentials 
 3.3 Limitations of current pain assessment methods 
On a critical note, the currently available pain assessment tools have a number of limitations. First, 
they cannot satisfactorily distinguish pain from anxiety, stress or other emotional states.[58] 
Second, application of a particular tool in different contexts and circumstances, such as severity-of-
illness and diagnosis, can be problematic. For example, lethargy, stiff limbs, minimal movement and 
grunting all predict severity of illness,[59] but may significantly affect the total score. Third, they 
may be subject to a certain degree of subjectivity from the observer, who may or may not know 
how the child usually reacts to pain and may interpret certain behavior like less movement as 
reflecting being comfortable, when in fact the child holds still because of pain. 
Physiology-based assessment methods such as NIRS, skin conductance and heart rate variability 
also have their limitations. Overall, they measure either the sympathetic nervous system activity or 
a cortical brain response to a stimulus. Sympathetic activity may reflect pain, but is also associated 
with stress, anxiety and delirium. Also, vasopressor agents may influence sympathetic tone. A 
cortical brain response to a stimulus may be indicative of nociception, but does not tell us directly 
whether a stimulus is perceived as painful. For example, in a study using NIRS,[28] cortical brain 
responses were not altered by the administration of oral sucrose solution, whereas observational 
pain scores decreased significantly. 
Practical aspects of performing such measurements also impede the use of physiological tools. As 
an example, pupillometry can only be done in subjects with eyes opened. Infants are unable to 
collaborate and measuring the pupil diameter could become another stressful event. Lastly, aEEG 
measurement has been used for research purposes but has not yet been shown a useful marker for 
pain and analgesia in newborns and young infants.[60-63] 
 
3.4 Item Response Theory 
Pain assessment tools include several behavioral and/or physiological items. However, the items 
may not be indicative of pain to the same extent. Item Response Theory, an advanced statistical 
technique, could give insight in the informativeness of each separate item: the highest grade of 
intensity in one item may be more indicative of pain than the highest grade of another item. A 
recent study applied this technique to both the COMFORT scale and the Premature Infant Pain 
Profile (PIPP) in term and preterm neonates.[64] The behavioral items corresponded best with 
pain; physiological items did less. A similar pattern was previously reported,[22] and now 
advanced statistics show that high ratings of some behavioral items corresponded better with high 
pain levels than other items. This should be taken into account when using such a scale in new 
clinical trials, or when developing new observational assessment tools.  
 
Despite numerous efforts to quantify pain, finding the optimal PD marker in infant pain studies 
remains a challenge.[65] We still have to rely on surrogate endpoints in neonatal and infant pain 
research. Beecher posed the problem of scientists’ and clinicians’ wishes to express subjective 
outcomes in objective measures research already 50 years ago and this problem has not yet been 
mitigated in infant and neonatal pain research.[66, 67] 
 
4. Clinical trials 
Clinical trials to evaluate dosing, efficacy and safety of paracetamol and morphine in infants and 
newborns have been performed rather unconventionally compared to the scientifically desired 
drug development process known from newly introduced drugs. Both drugs are not new at all and 
were both given newborns and young infants long before the first trials were performed. Several 
research groups started to evaluate the efficacy of analgesia during surgery[68] and ventilation[69] 
in the early 1990s. The first pharmacokinetic studies were also published.[70] Figure 2 presents a 
schematic overview of steps towards evidence-based pharmacotherapy (the desired way is 
illustrated by the black boxes) and illustrates that clinical research with morphine and paracetamol 
has followed the opposite way so far (as the white boxes indicate). The grey boxes indicate factors 
that influence the white and black boxes. These factors require further research to optimize 
analgesic research in neonates and infants. 
 
 
Figure 2. Schematic diagram of clinical research wi th morphine and paracetamol (white boxes) in practice. 
Black boxes represent new drugs to be studied. Dose finding and population PK/PD modelling with both  
internal and external validation are needed before comparative trials can be conducted and implementat 
ion into clinical practice will be possible.  
RCT: randomized controlled trial; pop PK/PD: population pharmacokinetics/pharmacodynamics; PCM:  
paracetamol  
 
Before those trials, it was generally believed that neonates were not capable of experiencing pain, 
therefore neonatal surgery often was performed without any analgesia.[71] Anand et al[54] 
showed significantly lower hormonal stress responses in an analgesia group of operated newborns 
and better neurologic outcome compared to placebo-treated neonates.  
These findings raised public and scientific interest in neonatal and infant pain research.[72] 
Consequently, several analgesic trials were performed since. These trials compared for instance the 
short-term outcomes of continuous and intermittent postoperative morphine in newborns and 
infants,[73] postoperative rectal paracetamol vs. morphine,[74] and routine morphine with placebo 
during endotracheal ventilation in preterm newborns.[75]  See tables 3a and 3b for the randomized 
controlled trials (RCTs) performed. Studies involving neonatal abstinence syndrome or without 
analgesic endpoint (for example endotracheal intubation facilitation) were excluded. 
 
Authors Year Sample 
size 
RCT study design Outcome Major limitation(s)
Barker et 
al[76] 
1995 27 Low vs. high loading dose 
diamorphine 
Adequate analgesia in both 
groups, high loading dose 
produced greater respiratory 
depression 
Pain was not the primary 
endpoint and assessed by 
hormonal stress response 
 
Wood et 
al[77] 
1998 88 Morphine vs. diamorphine in 
ventilated preterm neonates 
Reduced stress response in 
both groups, more 
hypotension in morphine 
group 
High morphine dose: 200 
mcg/kg in 2 hours and 25 
mcg/kg.hr in preterm 
neonates 
Pain assessed by 
hormonal stress 
response, no placebo 
control group 
Anand et 
al[78] 
1999 67 Morphine vs. midazolam vs. placebo 
in ventilated preterm neonates 
(NOPAIN pilot trial) 
Morphine and midazolam 
reduced PIPP scores, only 
morphine improved 
High midazolam loading 
dose and high morphine 
maintenance doses 
neurological outcome
Lynn et 
al[79]  
2000 83 Morphine continuous targeting 
predefined plasma level vs. 
intermittent bolus in infants 
postsurgery 
Continuous morphine 
provided better analgesia, 
morphine dosing was higher 
Power calculation 
performed on ventilatory 
endpoint 
Van Dijk et 
al[73] 
2002 181 Morphine continuous vs. intermittent 
postsurgery aged 0-3 year 
No difference in pain scores or 
morphine consumption 
No power calculation 
performed 
Simons et 
al[75] 
2003 150 Morphine continuous vs. placebo in 
ventilated preterm neonates 
No beneficial effect on pain, 
less IVH in morphine group, 
comparable composite 
outcome 
Rescue morphine not 
based on pain 
assessments 
Anand et 
al[80] 
2004 898 Morphine continuous vs. placebo in 
ventilated preterm neonates 
(NEOPAIN trial) 
No beneficial effect on 
neurologic outcome measures 
High morphine dose, no 
baseline for primary 
composite outcome 
Carbajal et 
al[81] 
2005 42 Morphine boluses vs. placebo for 
procedural pain 
No adequate analgesia in 
morphine group 
Continuous morphine 
used for procedure 
Taddio et 
al[82] 
2006 132 Morphine vs. Placebo vs. Tetracaine 
for central catheter insertion in 
premature neonates 
Beneficial effect of both 
morphine and tetracaine 
Morphine infusion 
allowed during 
intervention 
Table 3a. Randomized controlled trials with morphine in the young pediatric population. PIPP: 
Preterm Infant Pain Profile 
 
Authors Year Sample 
size 
RCT study design Outcome Major limitation(s) 
Howard et 
al[83] 
1994 44 Paracetamol vs. placebo in neonates 
undergoing circumcision 
Minimal effect of paracetamol  Sweet solutions (both 
PCM and placebo) may 
have biased the results 
Crying time as pain 
endpoint 
Shah et al[84] 1998 75 Paracetamol vs. placebo 90 minutes 
before heel lance 
No effect of paracetamol No validated pain 
assessment tool 
Van der Marel 
et al[74] 
2007 54 Morphine vs. rectal paracetamol in 
postsurgery infants 
No effect of paracetamol High continuous 
morphine doses could 
have masked a clean 
paracetamol effect 
Van Lingen et 
al[85] 
2001 122 Rectal paracetamol vs. placebo after 
vacuum extraction 
No analgesic effect of 
paracetamol 
No validated pain 
assessment tool, rectal 
administration 
unreliable in neonates 
Bonetto et al 2008 76 Oral glucose vs. oral paracetamol vs. 
topical EMLA vs. placebo 
No effect of paracetamol No comment on inter-
observer variability of 
pain assessment tools 
Badiee et 
al[86] 
2009 72 Oral paracetamol vs. placebo 90 
minutes before heel lance 
No effect of paracetamol Time of administration 
could possibly be too 
early: no clear PK data 
on start of study 
Manjunatha et 
al[87] 
2009 18 Oral paracetamol vs. oral morphine 
vs. placebo 60 minutes before ROP 
screening 
No significant effect of 
morphine or paracetamol 
Underpowered 
(calculated sample size 
was n=63) 
Tinner et 
al[88] 
2013 123 Rectal paracetamol vs. placebo after 
forceps or vacuum extraction 
delivery 
No effect of paracetamol Only 2 doses of 
paracetamol: no steady-
state 
Seifi et al[89] 2013 120 Oral acetaminophen vs. oral sucrose 
vs. placebo 
No effect of paracetamol Paracetamol 
administered 30 
minutes before ROP 
screening 
Ceelie et al [3] 2013 71 Morphine vs. IV paracetamol in 
postsurgery infants 
Significant reduction of 
morphine consumption 
Single-center study 
Table 3b. Randomized controlled trials with paracetamol in the young pediatric population. IV: 
Intravenous; ROP: Retinopathy of Prematurity 
 
In the earlier trials, dosing regimens were based on scarce neonatal pharmacokinetic data.[70, 90] 
Later trials used dosages based on population PK/PD models derived from these early trials.[1, 3] 
Besides optimizing dosing regimens in clinical practice, this evidence-based dosing improved the 
quality of analgesic clinical trials. In the Ceelie et al trial[3] for example, a fairer comparison 
between paracetamol and morphine could be made, as morphine plasma levels across all ages were 
the same. In the Van der Marel et al trial,[74] which found no beneficial effect of paracetamol, the 
analgesic effect of paracetamol could have been masked by relatively high morphine plasma levels 
as their study population was very young.  
5. Pharmacokinetics/pharmacodynamics 
One of the major challenges in neonatal and infant drug research is the rapidly-changing 
pharmacology in this age group. Due to the rapid developmental changes in both the 
pharmacokinetics and the pharmacodynamics of a drug, a very heterogeneous population exists. 
These developmental changes will to a large extent determine the safety and efficacy of the studied 
drugs. Below, we will discuss the PK and PD of morphine and paracetamol as model drugs, to 
illustrate the importance of the changes throughout the first phase of life.  
5.1 Morphine pharmacokinetics 
5.1.1 Morphine metabolism 
Drug metabolizing enzymes are classified by the reactions they catalyze: phase I reactions including 
oxidation, reduction or hydrolysis and phase II reactions including glucuronidation, sulfation, 
methylation or acetylation. Traditionally, phase I enzymes such as the cytochrome P450 system 
have received more attention in pharmacologic research than phase II enzymes such as the uridine 
diphosphate glucuronosyltransferase (UGT) isoenzymes.[91] Morphine is glucuronidated by the 
UGT isoenzyme 2B7 into two active metabolites, morphine-3-glucuronide (M3G) and morphine-6-
glucuronide (M6G).[92]  
5.1.2 Maturation of morphine metabolism 
Maturation of glucuronidation significantly influences the clearance of morphine in neonates, and 
most of the maturation process takes place in the first few months. A first indication came from the 
work of Lynn et al[93] in a group of post cardiac surgery newborns and infants. Morphine clearance 
(expressed per kg bodyweight) was reduced in the first month of life but then increased to above 
adult levels. This pattern has been confirmed by two models derived from nonlinear mixed-effects 
modelling (NONMEM)[94] and clinical research, respectively. Bouwmeester et al[95] described that 
neonates in the first week of life required less morphine and had higher morphine plasma 
concentrations than thereafter, at the same mg/kg dosing regimen. These findings led to the 
development of a pharmacokinetic model for children up to the age of 3 years, including preterm 
neonates.[2] This model shows that the morphine glucuronidation capacity and the clearance of the 
glucuronides are influenced by bodyweight in a nonlinear manner (body-weight based power 
equation with an exponential scaling factor of 1.44). Furthermore, before the postnatal age of 10 
days, clearance and glucuronidation capacity was approximately 50% lower than thereafter. The 
resulting new model-based dosing advice recommended significantly lower doses, particularly for 
the youngest neonates, than the generally recommended 10-40 mcg/kg/hr.[1] It is thought 
therefore that neonates, especially aged <10 days, frequently may have been overdosed worldwide 
because of their low glucuronidation capacity. Figure 3 illustrates the plasma levels of morphine, 
M3G and M6G with the old vs. the new dosing regimen. 
 
 
 
Figure. 3. (a, d) Morphine concentrations, (b, e) morphine-3-glucuronide (M3G) concentrations, and (c, 
f) morphine-6-glucuronide (M6G) concentrations predicted in model-based simulations in children weighing  
0.5, 1, 2, 2.5 and 4 kg and a postnatal age of <10 days (dotted lines) and children weighing 0.5, 1, 2, 2.5,4, 10 
and 17 kg and a postnatal age of >10 days (solid lines) based on (a–c) a dosing regimen with a  
loading dose of 100 mg/kg and maintenance dose of 10 mg/kg/h and (d–f) a regimen with a loading dose of  
100 mg/kg followed by an infusion of 10 mg/kg1.5/h with a 50% reduction in the maintenance dose for  
children with a postnatal age <10 days. Reprinted with permission from: Knibbe, C.A, et al., Morphine 
glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet, 2009. 
48(6): p. 371-85 
 
5.1.3 Model-based dosing 
As this increase in clearance at day 10 after birth may be considered an arbitrary cut-off, Wang et al 
further evaluated morphine pharmacokinetics and, using a wider population, developed a 
bodyweight-dependent exponent (BDE) model. The BDE model predicted clearance across the 
entire pediatric age range better than the model with a fixed exponent of either 0.75, the ‘classical’ 
allometric scaling exponent, or the age-dependent exponent of 1.44.[96] While for neonates and 
infants below 1 year, the dosing schedule hardly differs between these two models, the next step in 
pediatric morphine research is evaluating this morphine dosing regimen based on the BDE model 
for other indications than postoperative pain after major non cardiac surgery.[1] An observational 
study, for example, showed that higher dosages for NEC are required, most likely because this is a 
very painful condition.[97] These studies are important because so far the model-based dosing 
guidelines[1, 96] are only corrected for differences in PK and not for type of pain or severity of 
illness. 
5.1.4 Factors contributing to variability 
Despite this progress in optimizing exposure to morphine in infants by correcting for structural 
pharmacokinetic differences as a result of developmental changes, there is still a large random 
variability in morphine clearance,[98, 99] with the highest variability in critically ill neonates. This 
may perhaps be attributed to variability in hepatic and renal function and hepatic blood flow, which 
in turn are influenced by positive pressure ventilation.[100] Other factors such as therapeutic 
hypothermia,[101] extracorporeal membrane oxygenation (ECMO)treatment [102] or type of 
surgery[93] may also be influential. 
Furthermore, it cannot be excluded that genetic differences play a role here. As an example, single 
nucleotide polymorphisms (SNPs) in the gene encoding for UGT2B7 have been shown to alter the 
pharmacokinetic parameters in adolescents.[103] The drug transporter P-glycoprotein, also known 
as MDR1 or ABCB1, may alter pharmacokinetics of morphine,[104] as well as organic cation 
transporter 1 (OCT1) and ABCC3.[105] So far, however, the effects of pharmacogenetics on 
pharmacokinetics in children have been rarely studied. Large sample sizes are needed to 
demonstrate a significant contribution of certain SNPs, because some SNPs occur only in 1-5% of 
the population. Sufficiently large sample sizes can most likely be achieved only in (international) 
multicenter studies. 
5.1.5 Plasma concentrations vs. central nervous system concentrations 
While to date most developmental changes in plasma pharmacokinetics of morphine have been 
characterized, another source of variability could be the distribution into the CNS. As the blood-
brain-barrier (BBB) prevents a 1:1 concentration ratio of many substances between brain 
interstitial fluid and plasma, targeting certain plasma concentrations may not adequately reflect 
desired CNS concentrations. Therefore, insight in the transport of morphine and its active 
metabolites across the BBB will contribute to individualized dosing. So far, only a few 
pharmacokinetic studies have considered concentrations in the cerebrospinal fluid (CSF) in 
humans, and such studies in children are rare, and completely missing in preterm newborns.  
One of the studies in adults showed an increase of the CSF:plasma morphine concentration ratio 
from 0.2 to 0.6 over a two-hour period.[106] Another study in patients with chronic use of oral 
morphine reported a ratio of 0.9,[107] suggesting that reaching a steady-state balance between 
both compartments takes some time. In children, only one study so far has linked serum and CSF 
concentrations of morphine[108] after a single infusion. The plasma:CSF concentration ratio was 
nearly 1:1after two hours. For M6G, this ratio remained about 10:1, as this metabolite is less 
lipophilic. This finding could be relevant, as it is being debated whether morphine itself or M6G is 
the most important pain relieving substance.[109, 110] M3G, which circulates in substantially 
higher concentrations than morphine and M6G, is thought to lead to adverse effects such as 
hyperalgesia, particularly upon prolonged use when this metabolite accumulates.[111, 112] Studies 
have shown that M3G accumulates in critically ill patients, even after a 33% dose reduction.[112, 
113] Morphine plasma levels decreased, but M3G levels remained the same after this dose 
reduction, indicating that M3G could be highly responsible for side-effects in this specific 
population. This is an important finding and the role of M3G in morphine safety should be studied 
further.  
Even though attempts have been made to describe the CNS pharmacokinetics of morphine, the full 
picture is not yet clear. The BBB is changing throughout childhood, and the fact that the P-
glycoprotein drug transporter is less readily available in the neonatal brain could mean an increase 
in diffusion of morphine into the brain.[104, 114] Unfortunately, no human data are available to 
confirm this. Animal models using microdialysis have shown a higher morphine influx in premature 
sheep than in adult sheep.[115] Also, morphine efflux out of the brain is reduced in premature rats 
compared to adult rats.[116] In pigs, the plasma:CSF transfer ratio decreased from 0.7 to 0.5 during 
the first 6 weeks of life, which was not statistically significant.[117] Nevertheless, data of animal 
models cannot easily be extrapolated to humans, notably in view of the considerable differences in 
BBBs across species.[118] Moreover, it is very likely that the BBB and related morphine diffusion 
have undergone changes in CNS disorders such as meningitis and encephalitis. 
5.2 Morphine pharmacodynamics 
5.2.1 PK-PD relationship 
The pharmacokinetic research described above centralized the plasma concentrations of morphine, 
but unfortunately the pharmacodynamic effects of morphine greatly vary between infants, even at 
similar plasma concentrations. It is known that analgesic needs in general depend on the type, 
severity and duration of pain. In relation to postoperative pain, morphine requirements depend on 
duration and severity of surgery but also on the type of surgery, such as cardiac or abdominal 
surgery.[3] Newborns operated on for NEC need much higher morphine dosages postoperatively 
than newborns operated on for other conditions.[97]  
Efforts to establish a minimal effective plasma concentration or a therapeutic window have not led 
to a clear target[119] and a concentration-response curve is lacking.[120] Future research should 
aim for specific plasma targets for different types of pain or procedures. 
5.2.2 Development of morphine sensitivity 
Postmenstrual age may play a role in morphine sensitivity, due to maturation of nociceptive 
pathways. Morphine exerts its effects mainly on the mu-opioid receptor and to a lesser extent on 
the kappa- and delta opioid receptors.[121] Sensitivity to morphine seems to be higher at neonatal 
age, although this has been suggested merely in rat models.[122] However, human neonates[3] 
below the age of 10 days needed significantly less rescue morphine than older neonates despite 
similar morphine plasma levels.[1] This could be due to less capability of pain expression, or to a 
higher BBB permeability for morphine. Another explanation may lie in the postnatal reorganization 
of opioid receptor expression. In rats,[122] during the first 3 weeks of rat life, the mu-opioid 
receptor expression is downregulated in the A fibers, but remains unchanged in the C fibers. Also, in 
this period the central terminals of the A fibers are found in the superficial dorsal horn, whereas at 
adult age only C fibers project into the superficial dorsal horn and the A fibers project in the deeper 
lamina, suggesting a higher morphine sensitivity in the early weeks of life.  
5.2.3 Pharmacogenetics 
Pharmacogenetics may also play a role in morphine sensitivity. In human neonates, a combination 
of SNPs in two different genes, OPRM1 and COMT, was found associated with postoperative 
morphine consumption.[123] The same polymorphisms are associated with the severity of 
neonatal abstinence syndrome.[124] While OPRM1 is the coding gene for the mu-opioid receptor, 
COMT is a regulatory gene of mu-opioid receptor expression.[125] If both expression and function 
of the mu-opioid receptor are being disrupted by gene mutations, this could diminish the response 
to opioids.  
 5.3 Paracetamol pharmacokinetics 
Paracetamol is different from morphine with respect to safety and efficacy aspects. Paracetamol is a 
weaker analgesic, but on the other hand has a more favorable side effect profile. Still, the only side 
effect to take into account is probably more lethal than the opioid-induced respiratory depression, 
namely acute liver failure. In Western countries, paracetamol overdose is the most common cause 
of acute liver failure in adults and children.[126, 127] However, when kept within the therapeutic 
range, paracetamol provides analgesia as well as antipyrexia.  
5.3.1 Paracetamol metabolism 
Paracetamol is mainly metabolized by phase II enzymes to paracetamol-glucuronide and 
paracetamol-sulphate. Only a small fraction (1-4%) is excreted unchanged by the kidneys. The 
remainder is being metabolized to the hepatotoxic metabolite NAPQI through the action of 
cytochrome P450 (CYP) enzymes such as CYP2E1, CYP1A2, CYP3A4 and CYP2A6.[128] Under 
normal circumstances, reduced glutathione (GSH) neutralizes NAPQI very rapidly and the inactive 
cysteine and mercaptopuric metabolites are being formed and excreted renally. See figure 4 for the 
metabolic pathways of paracetamol. 
 
Figure 4. Metabolic pathways of paracetamol. Reprinted with permission from: Roofthooft, D.M.E. , 
Paracetamol and Preterm Infants: a painless liaison? PhD thesis, 2015, Erasmus University. 
 
5.3.2 Maturation of paracetamol metabolism 
Glucuronidation of paracetamol is very low in preterm infants and matures during early childhood, 
thus simultaneously increasing the relative contribution to paracetamol elimination[129] whereas 
the sulphation route remains fairly constant.[130] CYP enzymes mature during early infancy as 
well, but data on NAPQI formation in neonates are lacking. One modelling study in 47 patients could 
not attribute any clearance to oxidative pathways[129] However, as renal clearance is lower in 
neonates compared to adults, renal metabolite clearance may be reduced.[131] Expression of 
CYP2E1, the main isoenzyme responsible for NAPQI formation, increases during the first three 
postnatal months.[132] Whether NAPQI formation is reduced in this period remains unclear, but 
clinically there are no clues of NAPQI formation in neonates leading to hepatotoxicity, even at 
higher doses.[133]  
The pharmacokinetics of paracetamol in children for different administration routes is well-
described.[134-139] Population PK studies showed that weight is the most important predictor of 
paracetamol clearance in neonates.[131, 140] In a bodyweight-dependent exponent model, this 
relationship was found to be non-linear between children within the neonatal range and adults.[4] 
5.3.2 Factors contributing to variability 
There is, however, a great interpatient variability in paracetamol clearance.[130] For instance, 
clearance is lower in preterm neonates than in term neonates.[141] Paracetamol is being 
metabolized by many enzymes, thus the current role of pharmacogenetics is small. SNPs and 
mutations in metabolizing enzymes have been described, but often have not been studied in 
relationship to paracetamol.[142] Whether genetic variability influences the PK of paracetamol is 
hard to tell. If one or two metabolizing enzymes lose function due to genetic polymorphisms, other 
enzymes may take over. Differences in activity of transporters, epigenetic phenomena and organ 
specific activity of metabolizing enzymes probably all play a role. System biology-based modelling 
strategies may contribute to insight in the complex interactions between ontogeny, metabolic 
functions and genetics.[143] 
 
5.4 Paracetamol pharmacodynamics 
5.4.1 Unknown site of action 
While the pharmacokinetic basis for an evidence-based paracetamol dosing regimen has been 
established,[134-139] much groundwork remains to be done on the pharmacodynamics. For one 
thing, the exact mechanism of action remains unclear, even after comprehensive research.[128, 
144] Its primary target has been suggested to lie within the CNS, as cerebrospinal fluid 
concentrations corresponded better with analgesic response than did plasma concentrations.[145] 
In contrast, another study showed that analgesic response occurred earlier than changes in CSF 
plasma level.[146] A delay of the onset of action of the drug, a phenomenon called hysteresis, could 
perhaps explain why it is difficult to relate actual plasma and/or cerebrospinal fluid levels to a 
pharmacodynamics endpoint such as temperature or pain score. Therefore, Gibb and Anderson 
recommend to use indirect-response models to describe paracetamol PK and PD.[147]  
5.4.2 PK-PD-relationship 
As the mechanism of action is unclear, factors influencing the pharmacodynamic effects of 
paracetamol in children are hard to establish. The administration route, though, certainly has an 
impact on its effectiveness[3, 74, 138, 148] because of more favorable pharmacokinetics of the oral 
and intravenous routes compared to the rectal route.  
A dose-dependent response in children has been suggested when paracetamol was administered as 
treatment for both pain and fever.[149, 150] In general pediatrics, an adequate analgesic target 
plasma level of 10 mg/L is suggested.[148] It is unclear whether this target fits neonates and 
infants. Validation of these targets using validated assessment scales is necessary. Moreover, the 
question remains why there is a great variability in response. Whether this can be attributed fully 
to the action of paracetamol or to other factors such as the interpretation of the pain assessment 
tool needs to be studied further, especially as most trials studying the morphine-sparing effect of 
acetaminophen have been performed in older children.[151-153] 
Pharmacogenetics also does not help explain variability in response. This is mainly due to the lack 
of knowledge on the mechanism of action, impairing the search for relevant genes.  
 
6. Short-term and long-term side effects 
6.1 Morphine 
6.1.1 Short-term effects 
Morphine has several side effects, observed not only in adults but even more so in children and in 
neonates, such as respiratory depression, nausea, vomiting, constipation, urinary retention and 
hypotension. Hypotension in neonates, who are more vulnerable to changes in blood pressure,[80] 
may have severe consequences such as intraventricular hemorrhage (IVH) or periventricular 
leukomalacia (PVL). On the other hand, pain leads to an increased blood pressure which could also 
contribute to these sequelae. In a large RCT, the incidences of PVL and IVH were significantly higher 
in the placebo group compared to the morphine group.[80] In another RCT using lower morphine 
doses, IVH was also less frequent.[75] These data implicate that adequate analgesia may protect the 
brain on the short-term. Both clinical trials concluded, however, that routine administration of 
morphine in ventilated newborns should not be recommended. 
An important challenge is detecting side effects of analgesics in neonates and infants, as these can 
overlap with symptoms of their underlying disease. Structural proactive screening for side effects 
should take place in analgesic trials in the neonatal and infant population. 
6.1.2 Long-term effects 
Drugs administered when the child’s brain is still developing possibly interfere with  
Neurodevelopment.[154-156] This may especially be applicable to opioids, which directly act on 
the CNS. Moreover, in premature neonates, this interference may be even larger as the third 
trimester of gestation is important in CNS maturation. The current literature is not consistent 
regarding the long-term outcome of neonates receiving opioids. Some studies suggest alterations in 
neurological anatomy or structure,[154, 155, 157] but neuropsychological outcomes seem to be not 
affected by morphine exposure at neonatal age.[155, 158, 159] Follow-up trials cannot include a 
control group, as adequate analgesia is ethically obligatory and keeping neonates without opioids is 
highly undesirable. In the vulnerable preterms admitted to NICU who still receive a large amount of 
morphine,[160] morphine should not be considered the only causative factor for abnormal 
neurodevelopmental outcome.[157, 161]  
Schuurmans et al suggest a more standardized approach with large patient samples to detect small 
outcome differences.[162] Data about analgesics and long-term effects from such large studies are 
not yet available. Standardization of long-term follow up should include clinically relevant 
endpoints, preferably neuropsychological outcomes, especially executive function skills, as they 
determine a person’s functioning in daily life.[159, 163] 
 
6.2 Paracetamol 
6.2.1 Short-term effects 
Paracetamol is regarded very safe on the short-term. The major short-term side effect is acute liver 
failure, but no major hepatotoxic events have been reported so far in neonates.[133] 
 
6.2.2 Long-term effects 
Recent studies on atopy development associated with paracetamol exposure in early childhood are 
reason for concern[164-166] although they have important methodological limitations.[167, 168] 
Prospective studies should be performed to establish this potential causal link.[169] Such trials 
should at least incorporate pharmacogenetic assessment,[170, 171] although fundamental research 
on the mechanism(s) of action should pave the way for targeted pharmacogenetic research. 
 
6.3 Long-term effects of pain 
An important other challenge regarding the long-term effects of analgesics, is the long-term effect of 
pain itself. Pain exposure during early infancy also leads to alterations in brain structure[172, 173] 
and affects pain sensitivity in later life.[174] Finding an optimal balance between accepting long-
term opioid effects, on which the literature is still divided,[155, 175, 176] and the long-term effects 
of pain itself, is not yet feasible. Finding this balance could be supported by either more optimal 
dosing strategies, such as always starting with the lowest dose possible and up-titrate on the effect, 
taking into account inter-individual variability, or introducing alternative analgesics. This should be 
the aim of neonatal pain research in the near future, including larger sample-size studies.  
 
7. Premature neonates 
Special attention should be paid to (extreme) premature neonates when it comes to both pain and 
developmental clinical pharmacology. In the vulnerable premature neonate, pain is not only ‘an 
unpleasant sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage’, but is harmful on both the short and long-term.[172-174] 
These children daily undergo many potentially painful procedures,[177-179] while it is still unclear 
how to prevent or treat this pain optimally. What is more, the developing brain of the preterm 
infant is probably extremely vulnerable for the toxic effects of pharmacological agents, such as 
morphine.[154]  
Evidence from animal and human studies suggests an inverse relationship between 
postconceptional age and pain sensitivity, as measured by the reflex withdrawal test using von Frey 
hairs. However, whether this also means an increased pain sensation is doubtful as cortical pain 
responses seem to increase with increasing gestational age.[180] Nevertheless, little is known 
about the premature cortical pain processing and consequently the statement that (extreme) 
premature neonates feel more pain than their term peers is hardly based on solid methodological 
evaluation. At present the techniques to investigate these phenomena are far from ideal. Therefore 
investigators developed pain assessment tools based on the heel lance as a standardized painful 
procedure. Heel lancing is associated with an acute pain response that differs from more prolonged 
continuous distress and pain responses that are associated with preterm neonatal care. 
The pain experienced by neonates should be treated with adequate analgesics and preferably be 
prevented using the concept of pre-emptive analgesia. Morphine is recommended in several 
guidelines for the treatment of severe pain in premature neonates.[13, 181] The question arises 
whether the clearance of morphine differs between premature neonates and term neonates and if 
recommended doses can be used in extreme premature neonates. A recent study in extreme low 
birth weight neonates[182] compared five population PK models applied to their own prospective 
dataset of PK samples. The model based on data from extreme low birth weight infants[183] fitted 
best with their own dataset. The authors concluded that not only bodyweight but also maturation 
(including hepatic and renal function) contributes significantly to clearance, independently of 
bodyweight.  
For paracetamol, clearance changes non-linearly with bodyweight.[4] In premature neonates the 
paracetamol clearance matures more slowly than morphine clearance, and this could be attributed 
to the complex metabolism of paracetamol.[140] However, robust PK data in extreme preterm 
neonates are scarce[184] and in this population, more research is warranted on PK and its relation 
with both the analgesic effects and short and long-term neurodevelopmental outcomes.  
 
8. Expert commentary 
Neonatal and infant pain management and research have taken an extensive scientific journey so 
far. However, there is still a long way to go. The complex multimodality of pain comes along with 
major challenges in research. The first challenge is the assessment of pain. While current pain 
assessment tools merely reflect the outer circle of Loeser’s pain model, i.e. pain behavior, opioids 
and paracetamol act mainly on the nociception circle or the pain circle. This means that endpoints in 
pain research in children can only be surrogate endpoints. To measure analgesic effectivity, we 
should aim at biomarkers reflecting the direct effect of analgesics in the CNS. Attempts have been 
made with pupillometry, skin conductance and heart rate variability. These physiological, objective 
markers reflect sympathetic nervous system activity and are closer to the CNS. Near-infrared 
spectroscopy and somatosensory evoked potentials reflect the perception of a stimulus by the CNS, 
and are therefore promising in pain research. Multimodal studies, such as performed by Slater et 
al[28] and Hartley et al,[185] demonstrate lack of correlation between nociceptive brain activity 
and behavior at least in an experimental procedural pain study, which is a clear call for more 
clinical research.  
The other major challenge is optimal pharmacological pain treatment. Health care professionals 
need to take two important steps: choosing the right drug and defining the right dose. In order to 
choose the right drug, it is necessary to define type of pain first. From the clinical trials performed 
so far in neonates and infants, it seems that morphine is not the best choice for procedural and 
chronic pain, but has proven effectiveness for postoperative pain. Many clinics use fentanyl as an 
alternative to morphine and fentanyl or alternatively one of the synthetic derivatives is proven 
effective for procedural pain. Paracetamol (table 3b) seems to have no effect on procedural pain 
and a slight effect on postoperative pain. It is unknown whether it is effective for chronic pain. 
However, again it should be taken into account that these trials all have used surrogate endpoints 
and there is still a long way to go to determine true effectivity for each type of pain. 
The choice of drugs is also heavily influenced by the safety profile, and both morphine and 
paracetamol have been ascribed long-term negative effects without convincing evidence.[157, 161] 
These speculations call for well-designed trials with long-term outcomes as primary endpoints. 
Studies have been performed in different patient groups but with relatively small sample sizes and 
therefore underpowered to detect small differences in neurological outcome.[155, 186, 187] 
Dosing is also a major challenge due to both the rapid changing pharmacokinetics and 
pharmacodynamics in neonates and infants. Many population-based pharmacokinetic models have 
been developed for this population and have provided important data on the maturation of drug 
clearance. Still, there is no clear PK-PD relationship for morphine. PK is mainly focused on plasma 
levels, but PD effects are the result of morphine levels in the CNS. Further insight in the plasma:CNS 
relationship is necessary to define target plasma levels. The same holds for paracetamol, for which 
the PK is well-described for term neonates and infants but a PK-PD relationship also has great 
variability. 
 
9. Five-year view 
Pain assessment could possibly be improved by techniques reflecting CNS activity such as NIRS [28, 
29] or aEEG,[30] although the analyses and interpretations of these techniques are yet far from 
optimal to recommend their clinical use as pain measurement instruments. Functional MRI seems a 
promising method to look for specific brain areas involved in pain processing and the role of 
analgesics on these pain areas. Still, it should be kept in mind that activity in these areas does not 
always reflect pain, as these areas are also responding to stimuli in patients not capable of 
experiencing pain.[188] This technique should be further developed and applied in order to 
compare the ‘true’ effect of different analgesics, and comparative studies with both behavioral 
assessment tools, fMRI and/or NIRS/SSEP/aEEG may provide further insight in how to optimize 
pain assessment. Meanwhile, behavioral pain assessment tools are not to be forgotten. Application 
of the Item Response Theory[64] may identify the most pain-specific items of pain assessment 
scales and further improve bedside pain assessment. 
Furthermore, interactions between analgesics, for example paracetamol and opioids, deserve 
attention. A study already found that the use of paracetamol could reduce infants’ opioid 
consumption by 66% after major noncardiac surgery.[3] In our center, a similar trial is ongoing in 
cardiac surgery patients (the PACS trial; Dutch Trial Registry ID NTR5448). Trials like these could 
be a great opportunity to address the issue of long-term effects of both analgesics. 
The increasing knowledge of the ontogeny of drug metabolizing enzymes and drug transporters 
provides a good basis for a system-based approach of pediatric pharmacokinetics. This approach 
enhances the development of both individualized evidence-based pharmacotherapy of currently 
existing drugs and new analgesic drugs for children. Knowledge gained in the pharmacokinetic 
modelling of one drug could be applicable to other drugs as well. When specific properties such as 
logP and pKa of other drugs are applied to such models, clearance of these drugs can be predicted. 
Building such physiologically-based pharmacokinetic models may save the tremendous effort of 
describing PK of all drugs separately.[189]  
Other analgesics are also being introduced to neonatal and infant pain management. This review 
focused on morphine and paracetamol as model drugs, but fentanyl is also often used in the 
NICU.[13, 190, 191] Current use of fentanyl is based on little evidence, and its PK is highly variable 
in preterm neonates.[192] Studies performed with fentanyl are small.[193-195] This is a problem 
in most clinical trials involving neonates, especially in the NICU population. Therefore, to improve 
clinical research in this population, multi-center studies, if possible in established international 
consortia, could increase sample sizes. If this is not feasible, the required sample size may be 
reduced with the use of comparative effectiveness studies rather than superiority trials.[196]  
Another opioid which seems promising, especially for application in procedural pain, is 
remifentanil.[197-199] This very-short acting opioid is being metabolized by plasma esterases, 
independent of organ function or age. However, it does not automatically ‘do away with’ the dosing 
problem as its side effects such as chest wall rigidity can be age-dependent.[198] Caution is 
required with the clinical application of remifentanil.  
Lastly, the focus should be set on long-term effects. We do not know yet which analgesic is most 
harmful in the long-term, but must not forget pain is harmful anyway. Finding the optimal balance 
remains challenging[200] and calls for standardized long-term follow-up in neonatal pain trials. 
  
10. Key issues 
• Pharmacotherapy in neonates and infants is often not evidence-based. Finding the optimal 
design for clinical studies remains challenging. 
• Current pediatric drug research starts with clinical practice and ends up in more 
fundamental research. The other way round would be more conducive to evidence-based 
pharmacotherapy. 
• Pain is a biopsychosocial and subjective phenomenon and is therefore hard to assess.  
• The currently available pain assessment tools, both behavioral and physiological, for infants 
and neonates do not adequately differentiate between nociception and/or pain sensation on 
the one hand and stress or distress on the other hand. 
• Pharmacokinetics of morphine and paracetamol have been well described, even though 
there is still a great random variability in pharmacokinetics. The pharmacodynamics of 
morphine and paracetamol deserve further study with inclusion of ontogenic, 
pharmacological and genetic aspects. 
• Most literature focuses on plasma levels of analgesics, but insight in central nervous system 
pharmacokinetics is lacking. 
• Physiology-based pharmacokinetic models may serve as predictors of clearance which can 
be applied to multiple drugs. 
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